GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Greater Cannabis Co Inc (OTCPK:GCAN) » Definitions » COGS-to-Revenue

Greater Cannabis Co (Greater Cannabis Co) COGS-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Greater Cannabis Co COGS-to-Revenue?

Greater Cannabis Co's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

Greater Cannabis Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Greater Cannabis Co's Gross Margin % for the three months ended in Mar. 2024 was N/A%.


Greater Cannabis Co COGS-to-Revenue Historical Data

The historical data trend for Greater Cannabis Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greater Cannabis Co COGS-to-Revenue Chart

Greater Cannabis Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial 7.57 1.00 1.00 - -

Greater Cannabis Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Greater Cannabis Co COGS-to-Revenue Calculation

Greater Cannabis Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Greater Cannabis Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Greater Cannabis Co  (OTCPK:GCAN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Greater Cannabis Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Greater Cannabis Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Greater Cannabis Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Greater Cannabis Co (Greater Cannabis Co) Business Description

Traded in Other Exchanges
N/A
Address
15 Walker Avenue, Suite 101, Baltimore, MD, USA, 21208
Greater Cannabis Co Inc ia a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid therapeutics. The firm focuses on cannabis-related investment and development opportunities through direct equity investments, joint ventures, licensing agreements, or acquisitions and also on commercializing its eluting transmucosal patch platform (ETP) technology. The company's operations are focused on its online store, GCC Superstore. The firm is involved in additional research and development of innovative cannabinoid-based therapeutics.
Executives
Jimmy Wayne Anderson 10 percent owner 501 1ST AVENUE NORTH, SUITE 901, ST. PETERSBURG FL 33701